While anifrolumab targets IFN alfa in SLE, its unclear how much IFNa is needed for Rx response. A study of 40 pts shows Rx naive SLE has signif higher serum IFN activity; this is assoc w/ fever, leukopenia, ALE rash and oral ulcers & more organ damage https://t.co/nhqg0ky7RT https://t.co/kBuqvJYFYE

"My eye is swollen": an underrecognized mimic of IgG4-related disease Artem Minalyan, MD, presenting his poster at RWCS 2023. https://t.co/N2VShY5OHY https://t.co/fQYbFH6Mnb

Treat-to-Target Guidelines for GCA and PMR The Annals of Rheumatic Disease has published updated multinational, T2T recommendations for the treatment of giant cell arteritis (GCA) and polymyalgia rheumatica (PMR). https://t.co/zb0PXsW5mw https://t.co/PdFd9A794O

FDA has approved sarilumab (Kevzara) for the treatment of polymyalgia rheumatica (PMR) in adult patients who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. Approval is based on Phase 3 SAPHYR study https://t.co/7GHG2uG9yQ https://t.co/MZ7RYGdDfG

Triad of Trouble: A case of joint, skin and GI woes Sara Faghihi Kashani, MD, presents her poster at RWCS 2023 https://t.co/xwT2jV1gJv https://t.co/g63tRHsoQY

Sarilumab is FDA Approved for PMR The FDA approved sarilumab for PMR, stipulating it is indicated in those patients who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. https://t.co/VjzloCbpBv https://t.co/9dVb6sVbph

"My eye is swollen": an underrecognized mimic of IgG4-related disease Artem Minalyan, MD, presenting his poster at RWCS 2023. https://t.co/1j3FMazdyk https://t.co/K7VoQHhhGz

Without head-to-head trials, do we look to metanalyses? 13 trials of TNF inhibitors in JIA pts - Results at 12-14 weeks. While it ADA looks possibly better, that would be an over-interpretation and misuse of trial data that isnt truly comparable https://t.co/k6QcPZZj67 https://t.co/SwwND1VFfT

51 Juvenile SLE (j-SLE) studied for neuropsychiatric Dz (j-NPSLE)- 39% presented with jNPSLE. While no clear biomarker/imaging of j-NPSLE identified, they found CSF neopterin (& IFN-α) levels signif higher w/ active j-NPSLE & CNS involvement (p=0.0008) https://t.co/QM8yJGrBJu https://t.co/4hj1eE2JIC

Study of 87 pts with isolated Nail Psoriasis noted that 11% went on to have #PsA (concurrently or within 3 years). NP findings were mainly onycholysis in79% and nail pitting in 70% https://t.co/2NynITxe6B https://t.co/qs4uYySjxp

Mycobacterium Tuberculosis Osteomyelitis in a Patient on Pembrolizumab Jourdan Frankovich, MD, presents her poster at RWCS 2023. https://t.co/198oMm7GRa https://t.co/Qnh1sOOl6s

PsA: Depressing News on Second- and Later-Line Treatments Most patients with PsA failed to achieve low disease activity after switching from one targeted therapy to another, real-world data from Scandinavian registries indicated. https://t.co/7tSzoNLVoD https://t.co/3oUM4E38b1